Pacira Pharmaceuticals’ (PCRX) “Sell” Rating Reiterated at BMO Capital Markets

pacira-pharmaceuticals8217-pcrx-8220sell8221-rating-reiterated-at-bmo-capital-markets.jpg

Pacira Pharmaceuticals Inc. (NASDAQ:PCRX)‘s stock had its “sell” rating reiterated by stock analysts at BMO Capital Markets in a research report issued to clients and investors on Thursday.
Several other analysts also recently commented on PCRX. Mizuho initiated coverage on Pacira Pharmaceuticals in a research note on Tuesday, April 19th. They issued a “buy” rating and a $79.00 price objective for the company. Wedbush reissued an “outperform” rating and issued a $113.00 price objective on shares of Pacira Pharmaceuticals in a research note on Wednesday, April 20th. Canaccord Genuity reaffirmed a “buy” rating on shares of Pacira Pharmaceuticals in a report on Wednesday, April 20th. Zacks Investment Research raised Pacira Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, April 26th. Finally, TheStreet lowered Pacira Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, May 2nd. Two investment analysts have rated the stock with a sell rating, three have given a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $73.64.
Shares of Pacira Pharmaceuticals (NASDAQ:PCRX) traded up 4.42% during trading on Thursday, reaching $42.33. The company’s stock had a trading volume of 1,055,901 shares. The stock’s market cap is $1.58 billion. Pacira Pharmaceuticals has a 52-week low of $31.08 and a 52-week high of $80.25. The stock has a 50-day moving average of $41.07 and a 200-day moving average of $45.86.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/18/pacira-pharmaceuticals-pcrx-sell-rating-reiterated-at-bmo-capital-markets.html

Pacira Pharmaceuticals (NASDAQ:PCRX) last issued its quarterly earnings data on Thursday, August 4th. The company reported $0.19 EPS for the quarter, topping the consensus estimate of $0.03 by $0.16. The firm earned $69.60 million during the quarter, compared to the consensus estimate of $67.80 million. Pacira Pharmaceuticals had a positive return on equity of 0.02% and a negative net margin of 4.21%. The company’s quarterly revenue was up 17.8% compared to the same quarter last year. During the same period in the prior year, the business posted $0.20 earnings per share. Analysts predict that Pacira Pharmaceuticals will post $0.42 earnings per share for the current fiscal year.
In other Pacira Pharmaceuticals news, CEO David M. Stack sold 15,000 shares of the stock in a transaction on Monday, August 15th. The stock was sold at an average price of $45.32, for a total transaction of $679,800.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, President James S. Scibetta sold 25,000 shares of the stock in a transaction on Monday, August 15th. The stock was sold at an average price of $45.21, for a total value of $1,130,250.00. The disclosure for this sale can be found here. Company insiders own 6.90% of the company’s stock.
Several large investors have recently bought and sold shares of PCRX. BlackRock Institutional Trust Company N.A. increased its stake in Pacira Pharmaceuticals by 0.7% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 908,647 shares of the company’s stock valued at $48,140,000 after buying an additional 5,903 shares in the last quarter. Daruma Capital Management LLC increased its stake in Pacira Pharmaceuticals by 1.6% in the first quarter. Daruma Capital Management LLC now owns 963,184 shares of the company’s stock valued at $51,029,000 after buying an additional 14,901 shares in the last quarter. State Street Corp increased its stake in Pacira Pharmaceuticals by 4.4% in the first quarter. State Street Corp now owns 1,109,611 shares of the company’s stock valued at $58,792,000 after buying an additional 47,096 shares in the last quarter. Stephens Investment Management Group LLC increased its stake in Pacira Pharmaceuticals by 10.0% in the fourth quarter. Stephens Investment Management Group LLC now owns 540,687 shares of the company’s stock valued at $41,519,000 after buying an additional 49,018 shares in the last quarter. Finally, BlackRock Group LTD increased its stake in Pacira Pharmaceuticals by 17.7% in the first quarter. BlackRock Group LTD now owns 23,054 shares of the company’s stock valued at $1,221,000 after buying an additional 3,472 shares in the last quarter.
About Pacira Pharmaceuticals
Pacira Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company is focused on the development, commercialization and manufacture of pharmaceutical products, based on its DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. Its primary focus lies in the development of non-opioid products for postsurgical pain control.

Receive News & Ratings for Pacira Pharmaceuticals Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Pacira Pharmaceuticals Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.

Be the first to comment on "Pacira Pharmaceuticals’ (PCRX) “Sell” Rating Reiterated at BMO Capital Markets"

Leave a comment

Your email address will not be published.

*